{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T14:31:23Z","timestamp":1756996283010},"reference-count":0,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2016,1,4]],"date-time":"2016-01-04T00:00:00Z","timestamp":1451865600000},"content-version":"vor","delay-in-days":18449,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[1965,7]]},"abstract":"<jats:p>The response in terms of urinary electrolyte excretion in a group of eight normal subjects to increasing doses of oral ethacrynic acid has been determined. The changes in urine acid excretion, and in plasma volume and electrolyte content have been assessed on another normal subfect and an edematous patient. The effects of ethacrynic acid upon renal concentrating and diluting mechanisms have been demonstrated in a dog. In normal subfects the maximum effective oral dose of ethacrynic acid is 150 mg. The natriuresis la8ts for 6 to 8 hours and reaches its peak 2 hours after the drug is taken. Ethacrynic acid provides greater excretion of chloride than of sodium ions and increases hydrogen ion and potassium loss. This pattern of urinary electrolyte excretion is unique and may induce metabolic alkalosis, in the persistence of which chloride depleUon is more important than potassium deficiency. The dmg probably inhibits sodium reabsorption in the proximal renal tubules and in the ascending limb of Henle's loop.<\/jats:p>","DOI":"10.1002\/cpt196564474","type":"journal-article","created":{"date-parts":[[2016,1,5]],"date-time":"2016-01-05T00:37:46Z","timestamp":1451954266000},"page":"474-485","source":"Crossref","is-referenced-by-count":6,"title":["Metabolic effects and site of action of ethacrynic acid"],"prefix":"10.1111","volume":"6","author":[{"given":"J. G. G.","family":"Ledingham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. I. S.","family":"Bayliss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,1,4]]},"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpt196564474","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpt196564474","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt196564474","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T13:34:15Z","timestamp":1699364055000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt196564474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1965,7]]},"references-count":0,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1965,7]]}},"alternative-id":["10.1002\/cpt196564474"],"URL":"https:\/\/doi.org\/10.1002\/cpt196564474","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[1965,7]]}}}